Friday, April 20, 2012

Revenues And Profits, There is a Difference

Healthcare markets are big.  Billion-dollar market sizes are not uncommon for markets that cater to millions.  Those large numbers can confuse those outside the industry, especially those who are critical of the industry.  


As the leading estimator of the market for vaccines, some of the heaviest traffic we get is from those who do not agree with the progress of the vaccine market in recent years, the anti-vaccine community. We are happy to be cited in these blogs, and we note that as business information experts we have reviewed at different times nutraceuticals, wellness programs and holistic businesses these websites might favor.


I cite one article here:
---
"According to market research firm Kalorama Information, vaccine sales should double, from $19 billion in 2009 to $39 billion in 2013 – five times the $8 billion in vaccine sales in 2004......soon we’ll be asked to roll up our sleeves for vaccines thought to prevent, “Alzheimer’s disease, AIDS, pandemic flu, genital herpes, malaria, tuberculosis, urinary tract infections, grass allergies, traveler’s diarrhea, addiction and relapse – you name it, the pharmaceutical industry is working on a vaccine to supposedly prevent it."
--


That is an accurate quote of our report. Now we'll stay out of debate of personal decisions to accept a vaccine or not. I'll leave it to these websites to argue the merits of vaccination or whether parents should decide to vaccinate. Though we are experts in healthcare business opportunities, science and personal liberty are best for others to argue.


In most of these articles, revenues and profit are confused. An article will say 'Look at the profit the vaccine industry is making' and then cite our revenue number.   But revenues are very different from profits.  It is not uncommon for a company to make big revenues but lose money in the process.


Kalorama estimates revenue rather than profit generally, as revenue can broadly define the opportunity for an entire industry, where as profit is better left to analysts tracking individual companies about how well they are performing.


Profits are somewhat smaller in vaccines, though there are less marketing costs than in traditional sales. CSL Biotherapies, a good model as they are mostly a vaccine company. They made 4.1 billion in 2011 but most of that money went to materials, facilities or employees. Only 21% or revenues went to profit.

Wednesday, April 18, 2012

Increasingly, Healthcare Takes to Handheld Use

Kalorama finds in 2011 that hospitals got used to handheld technology in their daily workflow. Several factors are driving the growth of this market including a growing and aging population, shortage of qualified medical professionals, cost restraints, medical error reduction measures, government incentives, expanding capabilities of devices, off-site medical care and more.

Barriers in adopting new technologies include: access, cost, suspicion of its effectiveness, and a lack of confidence from new operators. However, record numbers of the general public are buying new handheld technologies from developers such as Samsung, HTC, and Apple. Buyers are purchasing smartphones and tablets for their own personal use, which provides a basis for implementing related technology in a work setting, such as a hospital. Not only are hospital personnel becoming more confident with new devices, more than half of hospital staff already have devices that can operate FDA-approved and HIPPA-compliant software.

One healthcare group, Hospital Corporation of America (HCA) reported in February 2012 that it would be continuing to invest in AirStrip Technologies, a mobile healthcare access provider. Airstrip offers physicians the technology to access real-time patient data on mobile devices, including the iPhone and Android devices.

As a whole, the healthcare industry is facing intense pressure to improve quality, control costs, and meet ever-changing government requirements. To meet these challenges, many health facilities are focusing on improving their workflow and restructuring their information system infrastructure. This Kalorama report takes a closer look at this growing opportunity and emerging technologies developed to meet new demands.

The newly updated report, Handhelds in Healthcare, addresses the growing market for handheld device markets in healthcare settings. For information or to order this report, please see http://www.kaloramainformation.com/Handhelds-Healthcare-Smartphones-6789230/

Monday, April 16, 2012

Fastest-Growing Area of Anesthesia Might Be: Drugs That Keep You Awake

Yes, its counter-intuitive, but the hottest sales area of the anesthesia drug market are for adjunctive therapies that assist the anesthesia process in some form. And anesthetic reversal agents is one category of complementary drugs.

Drugs that relax a patient’s muscles, relieve anxiety or wake patients up after surgery are growing faster in terms of revenues than the anesthetics themselves, according to the healthcare market research publisher.

The market for all anesthesia drugs including adjunctive drugs reached 5.3 billion according to Kalorama Information’s report, The World Anesthesia Drug Market (General, Local, Adjunctive), with fastest growth coming from the adjunctive category.

Adjunctive therapies include muscle relaxers such as Tracrium or Tubarine, Drugs that relieve anxiety prior to anesthesia such as Atropine or Diazepam have become a growing category. Drugs that can reverse anesthesia, reduce the effect of opioids and wake a patient, such as Flumazenil or Naloxone, have also seen intense competition and sales. Sales growth of these type of drugs will more than double growth of the overall anesthesia drug market, according to Kalorama Information’s report.

Companies such as Merck, Baxter, Roche, Abbott are among the competitors in this market. Competitive leadership in both the brand and generic markets will greatly depend on technology advancements and new formulations and delivery methods. The report finds that many products are currently reliant on the increasing number of surgical and diagnostic procedures worldwide of which will likely continue due to a growing population.

More detail on this market and specific numbers for drug categories are provided in Kalorama Information’s complete market research report on the topic. Important issues and trends are discussed in detail and companies are profiled in the report.

Friday, April 6, 2012

EMR Adoption: Some Are Skeptical About Adoption Gains

iHealthBeat has a good article presenting some skepticism of EMR adoption numbers. It includes Kalorama's estimate of the market from our new report EMR 2012.

Mitchell and some other observers believe that the growth in EHR acquisition will continue unabated. Research firm Kalorama Information recently reported that EHR sales were up 14.2% in 2011. Bruce Carlson, publisher of Kalorama's reports, told Healthcare IT News that sales would accelerate even further in the next two years because of Medicare penalties that will hit physicians who don't demonstrate meaningful use of EHRs, starting in 2015.

But DesRoches (Catherine DesRoches, senior scientist at Mathematica Policy Research
)is not so sure about that. She thinks that EHR adoption -- which already has leveled off for large groups -- might also plateau for small practices at some point, perhaps at a lower level than for the big groups. EHR acquisition is more difficult and financially risky for small practices than for large organizations, she pointed out. And, though cloud-based EHRs reduce some of the technical complexity, she said, EHRs as a whole are not becoming easier to use.

"Some practices may decide that the [government] incentives are not worth the cost of implementing the technology, or that the cost of implementing the technology outweighs the [Medicare] penalties," she observed.

It's a fair observation to make. Since 2007 Kalorama has noted slow uptake in adoption among confused smaller practices. Certainly the solo practices are not going to benefit as much as large group practices or health systems.

One of the things we've kept an eye on is Stark Exemptions that allow hospitals to subsidize affiliate physicians with EMR services. And the cloud services will help smaller practices adjust. Pharmacy and hospital use of EMR will make paper submission increasingly out of synch.

But in terms of our projection vs. the assessment of Mathematica's analyst may be that we are looking at 2 different factors. Adoption vs. revenue earned by vendors. There's plenty of revenue to be earned from a EMR sales, even wher adoption is slow, where even a minority of physicians are using EMR. Training and consulting on existing accounts will earn revenues for some providers, large hosptial buys represent the bulk of this market. Our reasonable growth rate assumes some continued resistance on the part of doctors. In fact a large adoption increase not resembling the growth rate we've seen so far would require a revision in revenue numbers.

That methodological difference being stated, we see a larger role for the disincentives than the article states, and we see the penalties in fact a bit more of a driver than the incentives.

Physicians are free to eschew incentive payments rather than invest, but will they tolerate a cut in Medicare/Medicaid income long term, especially where the penalty increases up to 2017, and perhaps could be increased after that point so that the government gets the paperless medicine it wants.

Wednesday, March 28, 2012

For Healthcare Marketers, Severability is Key

While political protesters have spent the past few days on the steps of the United States Supreme Court arguing for or against an individual mandate, for healthcare marketers it is today may be the most important day of oral argument. This was the day the Court was to consider the severability test on the healthcare reform bill of 2009. That is to say, if the idea of an individual mandate to purchase healthcare reform is unconstitutional in their interpretation, does the court throw out the rest of the law?

That will determine among other things if device makers face a new tax, or if a new tax would have to be re-enacted. A highly unlikely possibility in the current House of Representatives.

The argument of severability has legal scholars divided just as they are divided on the mandate. It could be argued that only the mandate portion is unconstitutional. But at least one Federal Circuit judge ruled the whole law unconstitutional, because lawmakers designed it as parts that would move together - mandate, prexisting condition discrimination ban, and subsidies. Taxes are designed to fund the subsidies. The logic is, if only the mandate is thrown out by the Court, then insurance companies would be unfairly punished -- all pain and no gain. All the burden of new insurees with pre-existing conditions without the gain of new healthy customers from the mandate.

This has increasing importance as watchers of the oral argument seem to agree that the mandate portion of the bill could be in danger with a court skeptical of the government's ability to order a citizen to purchase insurance or be penalized. Justice Anthony Kennedy's comments seemed to go in this direction:

Justice Anthony Kennedy said that the federal government "is telling an individual he has the obligation he must act" and purchase insurance.

"That threatens to change the relationship between the government and the individual in a profound way," Kennedy said.

And Chief Justice Roberts seemed to follow the same logic.

If Congress could regulate health care in the name of commerce, added Chief Justice John Roberts, "all bets are off" on a range of areas subject to federal oversight.

The mandate would determine if the healthcare industry will see millions of newly insured person, for its good and bad consequences to the industry. On one hand, there is the possibility of millions of device consuming, drug-taking, doctor-visiting customers, on the other primary care docs might see waiting rooms strained and hospitals may not be able to handle the influx for industries to ever see new revenue.

Friday, March 16, 2012

Will Pharmacies Push Docs to Adopt Electronic Records?

The government wants physicians to use EMR.  Affiliated hospitals in many cases would like physicians to use EMR.  And now, an additional encouragement comes from pharmacy chains.  According to this story in Fierce EMR, Walgreens' pharmacies and retail health clinics to share patient data directly to physicians electronically to improve the coordination of care.  7,800 Walgreens and Duane Reed pharmacies and 350 of its associated 'Take Care Clinics' retail clinics  will use Surescripts' network to deliver immunization data and patient summaries to physicians.

The good news about such a system is that physicians can check on their patients in terms of completing prescriptions, rather than having to take their word for it.  

We took note of this in the story, an accommodation for the not-so-paperless:

Cronin pointed out that while the project is designed to share information electronically, physicians will not be precluded from obtaining the information simply because they don't have an EHR. "We'll still get the information to them by fax or regular mail," as well, he said.
 So doctors do not have to use EMR to benefit from the program Still, Kalorama believes that with a major pharmacy chain now submitting information about patients that is easily to adapt into an EMR, the usefulness of adopting a system increases. The more EMR is relevant to all facets of practice, the higher adoption should grow.

Wednesday, March 14, 2012

Will the Real EMR Market Please Stand Up?


In what must be good news for the healthcare IT industry: EMR is growing.  Incentives, better patient outcomes, cost-savings EMR revenues grew 14.2%.  It doesn't mean the U.S. will have paperless medicine overnight, but the healthcare system is getting there, and some of the companies who help it along are making money.   How large is the market now?  That might vary according to what account you read. 

Each year since 2007, Kalorama Information has looked at the EMR market. Kalorama's latest study of the electronic medical records market estimates a market of over 17 billion dollars. We get a few questions from time to time about that number, because there are highly respected research firms with numbers in the single billions.  We can assure on this report that we have run the numbers by industry executives and they confirm or if anything say they are conservative.  Two things one should keep in mind.  a) We include 'Big EMR' if you will; the companies like McKesson, Cerner, GE Healthcare and the like as well as the smaller EMR companies.  b) we include ALL revenues related to the sale of an EMR: service fees, software, installation, training, CPOE.  Not including these would not reflect the real money that is being made in EMR.   Other estimates one sees in the press may only include software, or may exclude large companies who entered EMR by virtue of their strength in Patient Management IT. 

The revenue growth mirrors increased physician and institutional usage. Statistics from the National Ambulatory Medical Care Survey (NAMCS) indicate that 56.9 percent of the office-based physicians used partial or full EMR systems in 2011, an increase from the percent reported in 2010.  The first incentives were paid in 2011 based on 2010 performance. More than $1.3 billion in Medicare EHR Incentive Program payments have been made between May 2011 and the end of December 2011 and more than $1.1 billion in Medicaid EHR Incentive Program payments have been made between January 2011 and the end of December 2011.  We expect sales to grow further when the penalties are threatened , when Medicare and Medicaid could penalize providers who are not using certified EHRs by 2015.

The report can be found at Kalorama's website.